# A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp

> **NCT05387525** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Almirall, S.A.** · enrollment: 447 (actual)

## Conditions studied

- Keratosis, Actinic

## Interventions

- **DRUG:** Tirbanibulin (Klisyri®) 10 mg/g ointment
- **DRUG:** Diclofenac Sodium 3% Gel

## Key facts

- **NCT ID:** NCT05387525
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-24
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 447 (ACTUAL)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05387525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05387525, "A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05387525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*